Impaired inhibition of P2Y(12) by clopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention.

@article{ghannudi2011ImpairedIO,
  title={Impaired inhibition of P2Y(12) by clopidogrel is a major determinant of cardiac death in diabetes mellitus patients treated by percutaneous coronary intervention.},
  author={Soraya El ghannudi and Patrick Ohlmann and Laurence Jesel and Bogdan Radulescu and E El Adraa and Ulun Crimizade and Marie L Wiesel and Christian Gachet and Olivier Morel},
  journal={Atherosclerosis},
  year={2011},
  volume={217 2},
  pages={465-72}
}
OBJECTIVES We sought to determine whether low platelet response (LR) to the P2Y(12) receptor antagonist as assessed by vasodilator-stimulated phosphoprotein flow cytometry (VASP-FCT) differentially affects outcome in patients with or without diabetes mellitus undergoing percutaneous coronary intervention. BACKGROUND While both DM and LR to clopidogrel are… CONTINUE READING